Abstract:Cancer immunotherapy leads to long-term survival, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment (TME). A growing body of evidence indicates that intratumoral conventional type 1 dendritic cells (cDC1) are required to mount effective Tcell-mediated antitumor immunity and associate with better response to immune checkpoint blockade (ICB) therapy. However, approaches to generate cDC1s at clinical scale for immunotherapy have met limited success. We have previously demonstrated that overexpression of the transcription factors PU.1, IRF8 and BATF3 (PIB) drives cell fate reprogramming of cancer cells into functional antigen-presenting cDC1-like cells. Here, we investigated whether in vivo reprogramming of cancer cells into immunogenic antigen-presenting cDC1s can elicit systemic and durable antitumor immunity and explored the potential of in vivo delivery of PIB as a novel cancer immunotherapy modality. In vivo cDC1 reprogramming and antitumor efficacy were assessed upon subcutaneous implantation of in vitro transduced cancer cells in xenografts and ICB-resistant cDC1-dependent mouse syngeneic models. The impact of in vivo reprogramming in the TME was assessed using flow cytometry, single-cell transcriptomics, immunohistochemistry and microscopy. Tumor spheroids generated with human cancer cells in combination with cancer-associated fibroblasts or anti-inflammatory cytokines were used to investigate the impact of immunosuppressive microenvironment in cDC1 reprogramming. To select the optimal platform for in vivo delivery of PIB, we benchmarked PIB-encoding replication-deficient adenoviral (AdV), adeno-associated viral (AAV) and lentiviral (LV) vectors using mouse and human cancer cell lines and patient-derived cancer spheroids. Intratumoral delivery of PIB was performed in B16 syngeneic model to confirm in vivo efficacy induced by the gene therapy product.In vivo reprogramming to cDC1s drove complete responses (CR) in YUMM1.7 (100% CR), BRAFV600ECOX2KO (50% CR) and B2905 (80% CR) models and synergized with ICBs leading to 40% CR in B16 model, expansion of tumor-reactive T-cells and abscopal effect. Reprogrammed cancer cells recruited lymphocytes, promoted formation of tertiary lymphoid-like structures and expansion of polyclonal cytotoxic T cells. PIB-transduced human cancer cells acquired cDC1 and antigen-presentation markers in vivo with similar efficiency and kinetics as in vitro independently of immunosuppressive cells and cytokines. AdV was selected as the most efficient vector for in vivo delivery of PIB. Intra-tumoral injection of PIB-encoding AdV allowed in situ phenotypic reprogramming, enhanced infiltration of cytotoxic T cells and drove 50% CR, abscopal effect, long-term immune memory and protection against local and metastatic re-challenge. These findings provide preclinical proof-of-concept for an off-the-shelf, personalized cancer immunotherapy based on in situ cDC1 reprogramming, paving the way for first-in-human trials. Citation Format: Ervin Ascic, Fritiof Åkerström, Malavika Sreekumar Nair, André Rosa, Ilia Kurochkin, Olga Zimmermannova, Xavier Catena, Nadezhda Rotankova, Charlotte Veser, Michal Rudnik, Tommaso Ballocci, Tiffany Schärer, Xiaoli Huang, Maria de Rosa Torres, Emilie Renaud, Marta Velasco Santiago, Özcan Met, David Askmyr, Malin Lindstedt, Lennart Greiff, Laure-Anne Ligeon, Irina Agarkova, Inge Marie Svane, Cristiana Pires, Fábio Fiúza Rosa, Carlos-Filipe Pereira. A cancer immunotherapy modality based on dendritic cell reprogramming in vivo [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A021.

Abstract 7254: Evaluation of scFv and diabody pseudotyped Sindbis engineered retrovectors for targeted cancer therapy

Abstract 3534: Development of the Novel AAV-based Vectors with Selective Tropism to Human Cancer Cells

Abstract 2048: In vitro and in vivo characterization of non-oncolytic engineered arenavirus vectors for cancer immunotherapy

Abstract 7257: Examining the promise of precision medicine in immuno-oncology: Vectors for targeted therapeutic delivery

Abstract 3253: Novel gene & protein-carrying vector BC-PIV expressing immunomodulatory molecules potently stimulates anti-tumor immunity against solid tumors in mice

Abstract P32: Cell Type-specific Genetic Therapy of Cancer, Virus Infection and Mitochondrial Disease

Abstract 6225: Developing a novel combination therapy using engineered chimeric antigen receptor natural killer cells targeting avsialidase with avsialidase-armed oncolytic vaccinia virus in solid tumor models

Abstract A024: Systemic administration of CD3-redirected lentiviral vector efficiently targets CD19-CAR delivery to human T cells in vivo

Targeting Tumor Neoangiogenesis via Targeted Adenoviral Vector to Achieve Effective Cancer Gene Therapy for Disseminated Neoplastic Disease

812. Cellular Delivery of Gene Therapy Vectors

313. Development of the AAV6-Based Vectors with Selective Tropism and High Transduction Efficiency of Human Cancer Cells

Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met

Abstract 7260: An HSV-1-based vector for local delivery of IL-12 and IL-2 reshapes the immune landscape leading to tumor clearance and systemic immune surveillance

Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody

Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors

Abstract LB117: Virus-inspired Particles (ViPs) harnessing cytomegalovirus immune memory for local and systemic cancer immunotherapy

Abstract 5746: Flexible tumor-specific cytokine and antigen delivery through the T-SIGn vector platform enables effective CAR-T cell therapy against solid tumors

SYST-13 AAV VECTOR ENCODING FC MODIFIED HER2 ANTIBODIES REDUCES TUMOR BURDEN WITH MINIMIZED PERIPHERAL EXPOSURE IN MODELS OF BREAST CANCER BRAIN METASTASIS

Abstract 7239: Eradication of B cell lymphoma in a mouse model through in vivo transduction of T cells with an aCD19-CAR utilizing a CD3-targeted lentiviral vector

Abstract 5747: A novel combination therapy of arenavirus vectors and PD1-IL2v strongly potentiates tumor specific T cell responses resulting in synergistic anti-tumor efficacy

Abstract A021: A cancer immunotherapy modality based on dendritic cell reprogramming in vivo